OAM
BVS icon

Ophir Asset Management’s Bioventus BVS Stock Holding History

Ophir Asset Management’s Portfolio BVS Stock Details BVS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-424,708
Closed -$4.46M – 32
2024
Q4 		$4.46M Sell
424,708
-99,464
-19% -$1.18M 0.66% 29
2024
Q3 		$6.26M Buy
+524,172
New +$4.53M 0.96% 27

Other funds holding BVS

EWM
Essex Woodlands Management The Woodlands, Texas $251M AUM 13.72% 1-Year Est. Return
JIC
Juniper Investment Company New York $313M AUM 79.58% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
DSCM
Divisadero Street Capital Management Miami, Florida $2.39B AUM 134.55% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Ophir Asset Management's BVS Position: Q1 2025 in Review

Ophir Asset Management sold out of Bioventus (BVS) in Q1 2025, closing a stake of 424,708 shares — an estimated $4.46M sold.

Ophir Asset Management first reported a position in BVS in Q3 2024 and held it in 2 quarters. The position peaked at $6.26M in Q3 2024. 144 funds tracked by Wall St. Rank hold BVS as of Q1 2025.

  • Ophir Asset Management reported no remaining Bioventus position as of Q1 2025 after selling out during the quarter.
  • Ophir Asset Management sold 424,708 Bioventus shares in Q1 2025, an estimated $4.46M.
  • Ophir Asset Management first reported a position in Bioventus in Q3 2024 and held it in 2 quarters.
  • Ophir Asset Management's Bioventus position peaked at $6.26M in Q3 2024.
  • 144 funds tracked by Wall St. Rank held Bioventus as of Q1 2025.

Based on Ophir Asset Management's 13F filing for Q1 2025, filed 15 May 2025.